U.S. markets closed
  • S&P Futures

    4,328.25
    -15.00 (-0.35%)
     
  • Dow Futures

    33,698.00
    -100.00 (-0.30%)
     
  • Nasdaq Futures

    14,957.00
    -67.00 (-0.45%)
     
  • Russell 2000 Futures

    2,171.50
    -9.40 (-0.43%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,773.80
    -4.40 (-0.25%)
     
  • Silver

    22.47
    -0.14 (-0.62%)
     
  • EUR/USD

    1.1722
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.3240
    +0.0150 (+1.15%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3656
    -0.0008 (-0.06%)
     
  • USD/JPY

    109.2300
    +0.0100 (+0.01%)
     
  • BTC-USD

    40,720.86
    -1,059.42 (-2.54%)
     
  • CMC Crypto 200

    1,004.46
    -59.39 (-5.58%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,685.55
    -154.16 (-0.52%)
     

ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ObsEva SA OBSV announced that it has submitted a new drug application (“NDA”) to the FDA for its investigational oral GnRH receptor antagonist, linzagolix, for the treatment of uterine fibroids.

The NDA is based on data from two phase III studies, PRIMROSE 1 and PRIMROSE 2, which evaluated the safety and efficacy of linzagolix in patients with heavy menstrual bleeding (“HMB”) associated with uterine fibroids. During the 52-week treatment period, the patients were administered linzagolix in two dosing regimens of 100 mg and 200 mg once daily, with and without hormonal add-back therapy. Both the studies achieved their primary endpoints, as linzagolix significantly reduced HMB in comparison to placebo.

Please note that the data from the phase III studies was supported by data from the 76-week post-treatment follow-up study.

In the year so far, ObsEva’s stock price has risen 44.7% against the industry’s 1.2% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Uterine fibroids are common non-cancer tumors that grow on the uterus’ muscular tissue. Mainly affecting women of childbearing age, uterine fibroids are characterized by wide-ranging symptoms including HMB, anemia, pelvic pressure and bloating, urinary frequency, and extreme pain that can significantly impact the quality of life as well as mental health.

The dearth of long-term treatments for the indication makes hysterectomies the only viable option. Per the company, approximately 300,000 hysterectomies for uterine fibroids are performed in the United States alone each year.

With its potential approval in the United States, linzagolix will be the first oral GnRH antagonist to provide therapeutic alternatives for women who are unable to take hormone therapy. The drug will also become the company’s first marketable drug following approval.

It is to be noted by investors that the company has already received validation of the marketing authorization application in the EU for a similar indication. The company anticipates approval recommendation from the Committee for Medicinal Products for Human Use in fourth-quarter 2021.

Linzagolix is also being evaluated in a phase III EDELWEISS 3 study for the treatment of pain associated with endometriosis. Top-line data from the study is anticipated in fourth-quarter 2021.

We remind investors that ObsEva acquired the in-license rights of linzagolix from Japan-based pharma company Kissei in 2015. The rights also include global (excluding Asia) commercial rights for the product.

AbbVie’s ABBV elagolix has been approved by the FDA for the treatment of both HMB reduction in uterine fibroids and pain associated with endometriosis under the trade names Oriahnn and Orilissa, respectively.

ObsEva SA Price

ObsEva SA Price
ObsEva SA Price

ObsEva SA price | ObsEva SA Quote

Zacks Rank & Stocks to Consider

ObsEva currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the same sector include Regeneron Pharmaceuticals REGN and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Regeneron’s earnings per share estimates for 2021 have increased from $49.43 to $53.22 in the past 60 days. The same for 2022 has risen from $41.35 to $44.84 over the same period. The stock has rallied 33.6% in the year so far.

Vertex’s earnings per share estimates for 2021 have increased from $11.22 to $12.37 in the past 60 days. The same for 2022 has risen from $12.26 to $13.13 over the same period.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

ObsEva SA (OBSV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research